Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer
| Autor: | Tania Labiano, Alfonso Gurpide, Jose Angel Richter Echevarria, Maria D. Lozano, Carlos Caicedo, Javier J. Zulueta, Carmen Vigil Diaz, María José García-Velloso, Jose Luis Perez Gracia, José María López-Picazo |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty Mutation medicine.diagnostic_test biology Tumour heterogeneity business.industry General Medicine medicine.disease medicine.disease_cause respiratory tract diseases Positron emission tomography Internal medicine medicine biology.protein Carcinoma Radiology Nuclear Medicine and imaging In patient Epidermal growth factor receptor KRAS Lung cancer business neoplasms |
| Zdroj: | European Journal of Nuclear Medicine and Molecular Imaging. 41:2058-2065 |
| ISSN: | 1619-7089 1619-7070 |
| DOI: | 10.1007/s00259-014-2833-4 |
| Popis: | Purpose The tumour molecular profile predicts the activity of epidermal growth factor receptor (EGFR) inhibitors in non-small-cell lung cancer (NSCLC). However, tissue availability and tumour heterogeneity limit its assessment. We evaluated whether [18F]FDG PET might help predict KRAS and EFGR mutation status in NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|